Benzinga | Nov 2, 2020 04:17PM EST

Karyopharm Therapeutics Q3 EPS $(0.73) Misses $(0.72) Estimate, Sales $21.30M Miss $21.45M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 1.39 percent. This is a 8.96 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $21.30 million which missed the analyst consensus estimate of $21.45 million by 0.70 percent. This is a 61.99 percent increase over sales of $13.15 million the same period last year.